<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">bcp</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2014401</article-id><article-id pub-id-type="pmcid-ver">PMC2014401.1</article-id><article-id pub-id-type="pmcaid">2014401</article-id><article-id pub-id-type="pmcaiid">2014401</article-id><article-id pub-id-type="pmid">10930963</article-id><article-id pub-id-type="doi">10.1046/j.1365-2125.2000.00218.x</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation &#8211; intersubject variability in systemic absorption from the lung</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Minto</surname><given-names initials="C">Charles</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="B">Benny</given-names></name><xref ref-type="aff" rid="au2">2</xref><xref ref-type="author-notes" rid="fn2">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tattam</surname><given-names initials="B">Bruce</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brown</surname><given-names initials="K">Ken</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seale</surname><given-names initials="JP">J Paul</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Donnelly</surname><given-names initials="R">Richard</given-names></name><xref ref-type="aff" rid="au3">3</xref><xref ref-type="author-notes" rid="fn1">&#8224;</xref></contrib><aff id="au1"><label>1</label><institution>Department of Anaesthesia, University of Sydney</institution><addr-line>Australia</addr-line></aff><aff id="au2"><label>2</label><institution>Department of Pharmacy &amp; University of Sydney</institution><addr-line>Australia</addr-line></aff><aff id="au3"><label>3</label><institution>Department of Pharmacology, University of Sydney</institution><addr-line>Australia</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><italic>Correspondence:</italic> Dr Charles Minto, Department of Anaesthesia and Pain Management, Royal North Shore Hospital, St. Leonards, NSW 2065, Australia, Tel.: 61 29926 8420, Fax: 61 29906 4079, E-mail: <email>cminto@mail.usyd.edu.au</email>.</corresp><fn id="fn1"><label>&#8224;</label><p>Present addresses: School of Medical and Surgical Sciences, University of Nottingham, UK</p></fn><fn id="fn2"><label>*</label><p>Alcon Laboratories, Australia.</p></fn></author-notes><pub-date pub-type="ppub"><month>8</month><year>2000</year></pub-date><volume>50</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">151551</issue-id><fpage>116</fpage><lpage>124</lpage><history><date date-type="received"><day>07</day><month>6</month><year>1999</year></date><date date-type="accepted"><day>22</day><month>3</month><year>2000</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>02</month><year>2001</year></date></event><event event-type="pmc-live"><date><day>14</day><month>01</month><year>2008</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2014-04-15 11:51:20.030"><day>15</day><month>04</month><year>2014</year></date></event></pub-history><permissions><copyright-statement>&#169; 2000 Blackwell Science Ltd</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bcp0050-0116.pdf"/><abstract><sec><title>Aims</title><p>Pharmacokinetic variability is likely to be a significant factor contributing to the interindividual differences in dose requirements, anti-inflammatory response and side-effects with inhaled corticosteroids (ICS), but there is limited information about the disposition of ICS during regular dosing with a pressurized metered dose inhaler (pMDI). This study uses a mixed effects modelling approach to quantify and compare the interindividual variability in pharmacokinetics of epimeric budesonide (BUD) and fluticasone propionate (FP) after repeat-dose inhalation.</p></sec><sec sec-type="methods"><title>Methods</title><p>This pharmacokinetic substudy was part of a previously published open-label, randomised, placebo-controlled, 7-period crossover study to evaluate the short-term effects on plasma cortisol levels of inhaled BUD (400, 800, 1600 &#181;g twice daily) and FP (375, 750, 1000 &#181;g twice daily) via pMDI in a group of healthy male volunteers. On the fifth day of each high-dose treatment period (BUD 1600 &#181;g twice daily and FP 1000 &#181;g twice daily), venous blood samples were collected in nine subjects prior to the last dose and at 15 min, 30 min, 1, 2, 4, 6 and 8 h postdose for measurement of plasma drug concentrations to determine the pharmacokinetics of epimeric BUD and FP following inhalation. Non-compartmental analysis and a mixed effects model were used to characterize the disposition profiles.</p></sec><sec><title>Results</title><p>Both drugs had a rapid absorption half-life (BUD 10 min <italic>vs</italic> FP 11.3 min), but quite different elimination half-lives (BUD 2.4 h <italic>vs</italic> FP 7.8 h). Although there were intraindividual differences in the handling of the 22R-and 22S-epimers of BUD, there were no consistent pharmacokinetic differences between the two enantiomers in the group as a whole. Consistent with previous reports of FP&#8217;s higher volume of distribution (<italic>V</italic>) and lower systemic bioavailability (<italic>F</italic>), the <italic>V</italic>/<italic>F</italic> ratio was lower for BUD than FP (498 l <italic>vs</italic> 8100 l). The parameter with the greatest interindividual variability for both BUD and FP was the rate of systemic absorption from the lung.</p></sec><sec><title>Conclusions</title><p>This is the first report describing the pharmacokinetics of epimeric BUD and FP after repeat dose inhalation via pMDI. Three observations may be of clinical relevance: (1) there is considerable intersubject variability in the rate of absorption of both drugs from the lung; (2) in some individuals there was a long <italic>t</italic><sub>&#189;,z</sub> for BUD, resulting in higher and more sustained plasma drug levels in the 4&#8211;12 h postdose period than would be predicted from single-dose pharmacokinetic data; and (3) there is evidence of diurnal variation in FP pharmacokinetics, with higher-than-expected plasma drug concentrations in the morning compared with the evening.</p></sec></abstract><kwd-group><kwd>budesonide</kwd><kwd>fluticasone propionate</kwd><kwd>population pharmacokinetics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>